Advocacy Actions
Comments to NPC on Anti-Unfair Competition Law (Second Draft for Review)
On September 22, 2017, the European Chamber submitted feedback received from members regarding the call for comments on the second review draft of revision on Anti-Unfair Competition Law issued by the National People’s Congress (NPC).
Read moreLetter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Letter to Medical Insurance Department of MOHRSS on Drug Renaming in NRDL
Read moreComments on CFDA's Announcement 52, 53, 54, 55 on Encouraging Innovation in Pharmaceutical and Medical Devices
European Chamber Pharmaceutical Working Group submitted comments on CFDA's Announcement No. 52, 53, 54, 55 on encouraging innovation in pharmaceutical and medical device.
Read moreComments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
European Chamber Comments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
Read moreComments on Anti-unfair Competition Law (Draft Revision)
The European Chamber submitted consolidated comments from member companies to the National People's Congress on Anti-unfair Competition Law (Draft Revision).
Read moreSpeech at the 2017 International Pharmaceutical Innovation Forum in Nanjing
European Chamber Secretary General Mr. Adam Dunnett gave a keynote speech at 2017 International Pharmaceutical Innovation Forum in Nanjing, raising European businesses' recommendations on promoting innovation in China
Read moreLobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Lobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Read more